GDF-11

GDF-11 is a naturally occurring protein studied for its potential to support healthy aging and tissue renewal. It helps regulate how cells grow, repair, and communicate, especially in muscles, blood vessels, and the brain. Research suggests it may play a role in maintaining vitality and reversing some age-related changes in animals, though its effects in humans remain unclear.

Description

• GDF-11 (Growth Differentiation Factor 11) is a member of the transforming growth factor-beta (TGF-β) superfamily of proteins.
• It regulates cellular differentiation, tissue regeneration, and age-related remodeling processes.
• Studied for its potential role in reversing age-associated decline in muscle, brain, and vascular function.

How It Works

• Signals through activin type II receptors (ActRIIA/B), triggering SMAD2/3 transcription pathways.
• Promotes stem cell rejuvenation and inhibits excessive tissue hypertrophy in animal studies.
• Modulates systemic inflammatory and metabolic processes linked to aging.

Documented Effects

• Improved muscle strength and endurance in preclinical models of aging.
• Enhanced neurogenesis and vascular remodeling in laboratory research.
• Demonstrated cardioprotective and anti-fibrotic properties in rodents.

Theoretical Effects

• Potential anti-aging and regenerative applications under active investigation.
• May help balance stem cell renewal and tissue repair mechanisms.
• Could play a role in longevity research when combined with mitochondrial or senescence-focused peptides.

Pharmacokinetics

• Half-life: approximately 4–6 hours in circulation (based on preclinical data).
• Time to peak concentration: within 1–2 hours post subcutaneous injection.
• Steady-state: not achieved with intermittent dosing; GDF-11 acts in pulses for cellular signaling.

Duration of Effects

• Biological effects (e.g., changes in stem cell activity or vascular tone) may persist for several days after dosing.
• Repeated cycles may show cumulative improvements in animal models of aging.
• Mechanistic responses vary depending on tissue type and baseline activity.

Reconstitution

• Use only bacteriostatic water to reconstitute the lyophilized powder.
• Example vial: 1 mg of GDF-11
• Choose reconstitution volume based on dosing convenience:
  • 1 mL water → 1 mg/mL → 100 mcg per 10 units
  • 2 mL water → 0.5 mg/mL → 50 mcg per 10 units
  • 4 mL water → 0.25 mg/mL → 25 mcg per 10 units
• Swirl gently to dissolve; do not shake or heat.
• Refrigerate reconstituted solution (2–8 °C). Use within ~7 days for best stability.

Injectable Dosage Overview (Research Use)

Typical Starting Dose

• 10–50 mcg subcutaneous (SC) once every other day in small animal studies.
• Conservative start: 10 mcg to assess response and tolerability.

Common Research Range

• 10–100 mcg SC daily or every other day, depending on the experimental model.
• Often used in short study windows (1–3 weeks) for tissue response tracking.

Maximum Research Range

• Up to 200 mcg SC daily reported in rodent models with no additional effect beyond saturation.

Standard Cycle Length

• 1–4 weeks per cycle in research, followed by observation and biomarker tracking.
• Longer cycles may risk diminishing effects due to receptor downregulation.

Clinical Notes

• GDF-11 levels naturally decline with age, and supplementation studies remain preliminary.
• Often studied alongside myostatin inhibitors (e.g., Follistatin-344) for comparative effects.
• Exact dosing and safety for humans have not been established.
• Stable for about 7 days when refrigerated (2–8°C). Protect from light and heat. Avoid freezing.

Safety Notes (First-Time Use)

• Possible transient fatigue, mild headache, or injection-site redness.
• High doses may theoretically suppress muscle growth or alter tissue repair balance.
• Long-term data in humans are unavailable; use only in controlled laboratory settings.
• Research compound only; not approved for therapeutic human use.